

Lead selection of PD-L1xCD3 targeted immuno-ONCOLOGY (MB101) applying a novel bispecific antibody platform technology

MustBio Inc.



ONCOLOGY	Lead
Product Type	Immunoglobulin Product (Bispecific Antibody)
Indication	1st indication: NSCLC, Breast Cancer, Melanoma 2nd indication: Colorectal Cancer, Renal Cancer, Gastric Cancer
Target	Programmed Death-Ligand 1 [PD-L1] and Cluster of Differentiation 3 [CD3]
MoA(Mechanism of Action)	<p>MB101 inhibit PD-L1 and activates T cells, simultaneously. Therefore, MB101 could maximize an anti-tumor effect by tumor-directed immune activation rather than the systemic activation.</p>
Competitiveness	<ol style="list-style-type: none"> 1. Patented multi-specific Ab platform technology 2. Novel 2nd generation of anti-CD3 with improved safety profile 3. Superior anti-tumor efficacy compared to commercial ant-PD-L1
Development Stage	Lead
Route of Administration	Parenteral-intravenous